Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Novel agents in indolent lymphomas.
[waldenström macroglobulinemia]
Indolent
non-
Hodgkin
's
lymphomas
(
iNHLs
)
include
follicular
lymphomas
(
FL
)
,
marginal-zone
lymphoma
,
lymphoplasmacytic
lymphoma
/
Waldenström
macroglobulinemia
and
small
lymphocytic
lymphoma
.
First
-line
standard
therapy
in
advanced
,
symptomatic
iNHL
consists
of
rituximab-based
immunochemotherapy
.
The
recent
rediscovery
of
the
'
old
'
chemotherapeutic
agent
bendamustine
,
an
alkylating
agent
with
a
peculiar
mechanism
of
action
,
has
added
a
new
effective
and
well-tolerated
option
to
the
therapeutic
armamentarium
in
iNHL
,
increasing
response
rates
and
duration
.
However
,
patients
invariably
relapse
and
subsequent
active
and
well-tolerated
agents
are
needed
.
In
recent
years
a
large
number
of
new
targeted
agents
have
been
tested
in
preclinical
and
clinical
experimentation
in
FL
and
indolent
nonfollicular
lymphoma
(
iNFL
)
,
including
the
new
monoclonal
antibodies
binding
CD
2
0
or
other
surface
antigens
,
immunoconjugates
and
bispecific
antibodies
.
Moreover
novel
agents
directed
against
intracellular
processes
such
as
proteasome
inhibitors
,
mTOR
inhibitors
and
agents
that
target
the
tumour
microenvironment
,
notably
the
immunomodulatory
agent
lenalidomide
,
are
under
active
clinical
investigation
.
The
development
of
these
new
drugs
may
change
in
the
near
future
the
approach
to
iNHL
patients
,
leading
to
better
tolerated
and
effective
therapy
regimens
.
Diseases
Validation
Diseases presenting
"small lymphocytic lymphoma"
symptom
hodgkin lymphoma, classical
waldenström macroglobulinemia
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom